EichorEICHOR
Study identifier: NCT06694727 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: RecruitingDANUTRIO-HF

A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure

Condition: Heart Failure  ·  Sponsor: Tor Biering-Sørensen

PhasePhase 3
Planned participants4044
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
WhereHellerup, Denmark

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The study will assign approximately 4,044 patients from across Denmark to either coenzyme Q10 (100 mg twice daily) or a corresponding placebo, as well as selenium (100 μg twice daily) or its corresponding placebo, and follow how many of them end up being hospitalized for heart failure or dying from heart problems over an estimated two to three-year period.

This description comes directly from the study's public registry record.

Talk to the study team

Kristoffer G Skaarup, MD  ·  +4542451250  ·  kristoffer.grundtvig.skaarup@regionh.dk

Tor Biering-Sørensen, MD, MPH, MSc, PhD  ·  +4528933590  ·  tor.biering-soerensen@regionh.dk

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Individuals aged ≥ 18 years. * Registered with a heart failure diagnosis (ICD-10: I50) as a primary discharge diagnosis in The Danish National Patient Registry and at least one claimed prescription of a renin-angiotensin-system inhibitor and a β-blocker within 120 days after HF diagnosis. * Informed consent form has been signed and dated. Exclusion Criteria: * Use of vitamin K-antagonist * Registered with a cancer diagnosis (C00-C97 not C44) within the last 5 years excluding cutaneous squamous cell or basal cell carcinoma in The Danish National Patient Registry.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and GentofteHellerup, DenmarkRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Hellerup

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →